Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Sells $3,575,818.38 in Stock

by · The Markets Daily

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) CEO Christopher Richard Anzalone sold 51,726 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $69.13, for a total transaction of $3,575,818.38. Following the sale, the chief executive officer owned 3,805,926 shares in the company, valued at approximately $263,103,664.38. The trade was a 1.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Christopher Richard Anzalone also recently made the following trade(s):

  • On Monday, December 22nd, Christopher Richard Anzalone sold 12,586 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $68.44, for a total transaction of $861,385.84.
  • On Friday, December 19th, Christopher Richard Anzalone sold 13,445 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $67.66, for a total transaction of $909,688.70.
  • On Wednesday, December 17th, Christopher Richard Anzalone sold 85,000 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $64.04, for a total transaction of $5,443,400.00.
  • On Tuesday, December 16th, Christopher Richard Anzalone sold 54,298 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $62.58, for a total transaction of $3,397,968.84.
  • On Monday, December 15th, Christopher Richard Anzalone sold 130,000 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $68.85, for a total value of $8,950,500.00.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR stock traded down $2.37 during trading hours on Tuesday, hitting $67.25. The stock had a trading volume of 1,334,299 shares, compared to its average volume of 2,139,110. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86. The stock has a market capitalization of $9.14 billion, a price-to-earnings ratio of -840.52 and a beta of 1.28. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $72.36. The stock’s 50-day moving average price is $52.38 and its two-hundred day moving average price is $33.56.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ARWR shares. Morgan Stanley increased their target price on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 26th. HC Wainwright upped their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. Bank of America lifted their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Royal Bank Of Canada boosted their target price on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Finally, Piper Sandler upped their target price on shares of Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.89.

View Our Latest Research Report on ARWR

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ARWR. iSAM Funds UK Ltd purchased a new position in Arrowhead Pharmaceuticals during the 3rd quarter valued at $29,000. Salomon & Ludwin LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth $34,000. Virtus Advisers LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the second quarter valued at $34,000. Nisa Investment Advisors LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 75.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,308 shares during the last quarter. Finally, Federated Hermes Inc. purchased a new position in Arrowhead Pharmaceuticals in the 3rd quarter worth about $52,000. 62.61% of the stock is owned by institutional investors.

About Arrowhead Pharmaceuticals

(Get Free Report)

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.

Featured Articles